aleniglipron vs lixisenatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

Next expected readout: September 2028 · NCT07654374 (registry estimate)

Reported efficacy

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)

Result source: NCT05762471

lixisenatide · Adlyxin / Lyxumia

Marketed by Sanofi and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT00707031 · Phase 3 · completed

The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)

Result source: NCT00707031

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronlixisenatide
HbA1c, change—Trial running · NCT07654374-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473
Body weight, change (kg)—Trial running · NCT07654374-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
HbA1c below 7%—Trial running · NCT0765437453% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937
Fasting plasma glucose, change—Trial running · NCT07654374-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504
3-point MACE (% with event)—Trial running · NCT07654374—Not reported

HbA1c, change

aleniglipron
—Trial running · NCT07654374
lixisenatide
-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473

Body weight, change (kg)

aleniglipron
—Trial running · NCT07654374
lixisenatide
-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504

HbA1c below 7%

aleniglipron
—Trial running · NCT07654374
lixisenatide
53% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937

Fasting plasma glucose, change

aleniglipron
—Trial running · NCT07654374
lixisenatide
-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504

3-point MACE (% with event)

aleniglipron
—Trial running · NCT07654374
lixisenatide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo NCT05762471 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. aleniglipron: 0 of 4 rows · lixisenatide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriclixisenatide
Dropout rate
32.5%a
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.2%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
8.3%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
3.5%
NCT01147250 · Phase 3
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.8%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
10.5%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
11.9%
NCT01798706 · Phase 3 · registry result, not featured evidence
10.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
10.6%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
16%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
8.7%
NCT01169779 · Phase 3 · registry result, not featured evidence
13%
NCT00975286 · Phase 3 · registry result, not featured evidence
26%
NCT00763815 · Phase 3 · registry result, not featured evidence
27.5%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
22.4%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
10.1%
NCT00976937 · Phase 3 · registry result, not featured evidence
35.3%
NCT00715624 · Phase 3 · registry result, not featured evidence
30.9%
NCT00713830 · Phase 3 · registry result, not featured evidence
18.6%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
24.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
25%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
39.4%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
13.6%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
4.2%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
6.8%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
14.1%a
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
2.5%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
4.2%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
—
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.3%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
3.9%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
—
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
8.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
5%
NCT01768559 · Phase 3 · registry result, not featured evidence
4.9%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
4.4%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
5.6%
NCT01169779 · Phase 3 · registry result, not featured evidence
8.5%
NCT00975286 · Phase 3 · registry result, not featured evidence
9%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
2.5%
NCT00976937 · Phase 3 · registry result, not featured evidence
11.2%
NCT00715624 · Phase 3 · registry result, not featured evidence
12.4%
NCT00713830 · Phase 3 · registry result, not featured evidence
8.7%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
11.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
13.9%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
21.2%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
9.1%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
2.1%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
3.7%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
Serious AEs
8.2%a
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
0%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
0.8%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
20.6%
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.2%
NCT05413369 · Phase 3 · registry result, not featured evidence
3.9%Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
10.2%Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
5.5%
NCT02058160 · Phase 3 · registry result, not featured evidence
3.8%Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
3.9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
4.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
3.7%
NCT01768559 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
1.5%
NCT01169779 · Phase 3 · registry result, not featured evidence
7.6%
NCT00975286 · Phase 3 · registry result, not featured evidence
7.7%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
1.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
14%
NCT00715624 · Phase 3 · registry result, not featured evidence
10.1%
NCT00713830 · Phase 3 · registry result, not featured evidence
—Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
13%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
9.9%Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
2.8%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.1%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.5%
NCT00866658 · Phase 3 · registry result, not featured evidence
2.1%20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
—20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
5.6%
NCT01476475 · Phase 2 · registry result, not featured evidence
0%
NCT01175473 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nausea 28.6%
nasopharyngitis 15.4%
diarrhoea 15.1%
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 31 more results
nausea 20.2% (placebo 3.3%)
headache 7.6% (placebo 8.2%)
vomiting 6.7% (placebo 0%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 24.2% (placebo 3.3%)
headache 8.3% (placebo 8.2%)
dizziness 7.5% (placebo 3.3%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 21.7% (placebo 5.9%)
hypoglycaemia 20.1% (placebo 18.3%)
dizziness 8.5% (placebo 6.3%)
NCT01147250 · Phase 3
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 17.2%
covid-19 13.4%
nausea 12.1%
NCT05413369 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.8%
nausea 8.6%
diarrhoea 5.5%
NCT02787551 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
nausea 9.2%
diarrhoea 7.3%
NCT02787551 · Phase 3 · registry result, not featured evidence
mild asymptomatic hypoglycaemia 33.3%
hypercholesterolaemia 22.2%
mild gastrointestinal complaints 22.2%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
nausea 10.4%
nasopharyngitis 8.8%
headache 5.8%
NCT02058160 · Phase 3 · registry result, not featured evidence
nausea 9.6%
diarrhoea 9%
upper respiratory tract infection 7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 24%
diarrhoea 9%
headache 7.7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 25% (placebo 7.5%)
hypoglycaemia 17% (placebo 10.3%)
diarrhoea 10.8% (placebo 7.5%)
NCT01798706 · Phase 3 · registry result, not featured evidence
hypoglycaemia 35.9%
nausea 25.2%
blood glucose decreased 20.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
nausea 15.5%
headache 7.1%
nasopharyngitis 7.1%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 14.7%
nasopharyngitis 9.8%
hypoglycaemia 6.7%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 16.3% (placebo 2.6%)
hypoglycaemia 9.2% (placebo 4.6%)
dizziness 8.7% (placebo 4.1%)
NCT01169779 · Phase 3 · registry result, not featured evidence
hypoglycaemia 27.4% (placebo 19.3%)
nausea 27.4% (placebo 4.9%)
headache 9.9% (placebo 3.6%)
NCT00975286 · Phase 3 · registry result, not featured evidence
nausea 26% (placebo 13.7%)
nasopharyngitis 16.4% (placebo 14.9%)
headache 13.3% (placebo 11.8%)
NCT00763815 · Phase 3 · registry result, not featured evidence
nausea 24.7% (placebo 10.6%)
headache 16.5% (placebo 23.5%)
vomiting 15.7% (placebo 3.5%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 25.1% (placebo 10.6%)
headache 19.2% (placebo 23.5%)
diarrhoea 15.3% (placebo 11.8%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 17.7%
headache 12.7%
diarrhoea 8.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
hypoglycaemia 42.1% (placebo 40.7%)
nausea 29.3% (placebo 9.6%)
headache 12.5% (placebo 10.2%)
NCT00715624 · Phase 3 · registry result, not featured evidence
nausea 28% (placebo 8.8%)
hypoglycaemia 24.4% (placebo 19.3%)
nasopharyngitis 15.9% (placebo 20.4%)
NCT00713830 · Phase 3 · registry result, not featured evidence
nausea 37.9% (placebo 8.1%)
vomiting 18% (placebo 0.6%)
diarrhoea 14.9% (placebo 13.1%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 29.2% (placebo 8.1%)
vomiting 13% (placebo 0.6%)
headache 12.4% (placebo 12.5%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 50%
nasopharyngitis 36.1%
decreased appetite 19.4%
NCT00905255 · Phase 3 · registry result, not featured evidence
nausea 36.4%
nasopharyngitis 27.3%
decreased appetite 18.2%
NCT00905255 · Phase 3 · registry result, not featured evidence
hypoglycaemia 43.5% (placebo 23.6%)
nausea 39.6% (placebo 4.5%)
vomiting 18.2% (placebo 1.9%)
NCT00866658 · Phase 3 · registry result, not featured evidence
20 µg
decreased appetite 18.8%
nausea 18.8%
nasopharyngitis 12.5%
NCT01596504 · Phase 2 · registry result, not featured evidence
nausea 7.5%
nasopharyngitis 5.6%
headache 5%
NCT01476475 · Phase 2 · registry result, not featured evidence
nausea 22.1%
decreased appetite 18.2%
headache 11.7%
NCT01175473 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 32 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

lixisenatide

HbA1c -0.58% (n=46) vs -0.66% (n=44) Liraglutide @ 8wk20 µg
absolute change · percentage points
NCT01596504 · Phase 2 · registry result, not featured evidence
show 19 more results
-0.79% (n=295) vs -0.96% (n=297) Exenatide @ 24wk
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.88% (n=291) vs -1.68% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
-1.88% (n=291) vs -1.68% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
-1.13% (n=364) vs -0.62% (n=364) Insulin Glargine @ 30wk
NCT02058160 · Phase 3 · registry result, not featured evidence
-1.63% (n=467) vs -1.34% (n=464) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-0.85% (n=233) vs -1.34% (n=464) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-0.57% (n=172) vs 0.06% (n=172) placebo @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
-0.63% (n=292) vs -0.58% (n=292) Insulin Glulisine @ 26wk
NCT01768559 · Phase 3 · registry result, not featured evidence
-0.83% (n=185) vs -0.47% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
-0.71% (n=215) vs -0.4% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
-0.9% (n=308) vs -0.34% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
-0.66% (n=150) vs -0.72% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
-0.74% (n=304) vs -0.38% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
-0.85% (n=544) vs -0.1% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
-0.83% (n=152) vs -0.42% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-0.92% (n=156) vs -0.42% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-0.77% (n=146) vs 0.11% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
-1.82% (n=160) vs -1.64% (n=161) Insulin Glargine @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
-0.32% (n=75) vs -0.45% (n=67) Liraglutide @ 4wk
NCT01175473 · Phase 2 · registry result, not featured evidence
Fasting Plasma Glucose 0.1 vs 0.12 Liraglutide mmol/L @ 8wk20 µg
absolute change · mmol/L
NCT01596504 · Phase 2 · registry result, not featured evidence
show 17 more results
-1.22 vs -1.45 Exenatide mmol/L @ 24wk
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
-3.18 vs -3.45 IDegAsp mmol/L @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
-0.35 vs -0.46 Insulin Glargine mmol/L @ 30wk
NCT02058160 · Phase 3 · registry result, not featured evidence
-3.46 vs -3.27 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-1.5 vs -3.27 Insulin Glargine mmol/L @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-0.3 vs 0.01 placebo mmol/L @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
-0.23 vs -0.21 Insulin Glulisine mmol/L @ 26wk
NCT01768559 · Phase 3 · registry result, not featured evidence
-0.69 vs -0.21 placebo mmol/L @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
0.34 vs 0.46 placebo mmol/L @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
-1.16 vs -0.32 placebo mmol/L @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
-0.45 vs -0.69 Sitagliptin mmol/L @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
-0.63 vs -0.55 placebo mmol/L @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.36 placebo mmol/L @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
-0.56 vs 0.11 placebo mmol/L @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-0.53 vs 0.11 placebo mmol/L @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-0.42 vs 0.25 placebo mmol/L @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
-3.35 vs -3.51 Insulin Glargine mmol/L @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
Weight -1.61 vs -1.78 Liraglutide kg @ 8wk20 µg
absolute change · kg
NCT01596504 · Phase 2 · registry result, not featured evidence
show 17 more results
-2.96 vs -3.98 Exenatide kg @ 24wk
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.3 vs 1.19 IDegAsp kg @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
-0.67 vs 0.7 Insulin Glargine kg @ 30wk
NCT02058160 · Phase 3 · registry result, not featured evidence
-0.29 vs 1.11 Insulin Glargine kg @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-2.3 vs 1.11 Insulin Glargine kg @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
-1.47 vs -0.16 placebo kg @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
-0.63 vs 1.03 Insulin Glulisine kg @ 26wk
NCT01768559 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.24 placebo kg @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
0.28 vs 1.16 placebo kg @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
-0.21 vs 0.21 placebo kg @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
-2.51 vs -1.17 Sitagliptin kg @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
-1.8 vs -0.52 placebo kg @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
-1.76 vs -0.93 placebo kg @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
-2.68 vs -1.63 placebo kg @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-2.63 vs -1.63 placebo kg @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
-0.38 vs 0.06 placebo kg @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
-0.97 vs 0.48 Insulin Glargine kg @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 7% 48.5% (n=295) vs 49.8% (n=297) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 10 more results
72.5% (n=291) vs 59.8% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
53% (n=185) vs 38.8% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
56.3% (n=215) vs 38.5% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
52.3% (n=308) vs 26.4% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
40.7% (n=150) vs 40% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
28.3% (n=304) vs 12% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
36.4% (n=544) vs 13.5% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
42.1% (n=152) vs 24.1% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
47.4% (n=156) vs 24.1% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
35.6% (n=146) vs 5.2% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 28.5% (n=295) vs 35.4% (n=297) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 9 more results
32.4% (n=185) vs 18.1% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
32.1% (n=215) vs 16.3% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
28.9% (n=308) vs 10.1% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
24% (n=150) vs 26.3% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
14.5% (n=304) vs 3.8% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
19.3% (n=544) vs 4.7% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
20.4% (n=152) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
25.6% (n=156) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
17.8% (n=146) vs 1.3% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
Glycemic Rescue 2.2% (n=315) vs 3.8% (n=315) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
5.2% (n=291) vs 6.9% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
2.7% (n=366) vs 6% (n=365) Insulin Glargine
NCT02058160 · Phase 3 · registry result, not featured evidence
3.6% (n=468) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4% (n=233) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
2.9% (n=175) vs 10.4% (n=173) placebo @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
3.6% (n=195) vs 6.7% (n=193) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
0.4% (n=223) vs 0.4% (n=223) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
3.8% (n=320) vs 11.3% (n=159) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
9.5% (n=158) vs 6.8% (n=161) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
5.8% (n=327) vs 7.2% (n=166) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
4% (n=570) vs 12.6% (n=286) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
3.1% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=154) vs 3.2% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
0% (n=161) vs 0.6% (n=162) Insulin Glargine @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
Weight Loss 5% 25.1% (n=295) vs 31.4% (n=296) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
19.7% (n=188) vs 14.7% (n=191) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
5.1% (n=217) vs 3.2% (n=220) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
9.2% (n=315) vs 5.1% (n=157) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
13.2% (n=311) vs 3.1% (n=161) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
14.4% (n=554) vs 7.2% (n=278) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
25.8% (n=155) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
19.6% (n=158) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
7.3% (n=150) vs 4.5% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
HbA1c -0.73% (n=113) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
-0.85% (n=114) @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
-0.54% (n=9) @ 12wk
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
-0.65% (n=218) @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-0.74% (n=222) @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-0.87% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
-0.75% (n=239) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
PPG 2H -4.51 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 1 more result
-5.47 mmol/L @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
Weight -1.96 kg @ 12wk
absolute change · kg
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
-1.92 kg @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
-1.4 kg @ 12wk
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
-2.6 kg @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-2.8 kg @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-2.01 kg @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
-2.02 kg @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -0.68 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
-0.89 mmol/L @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
-0.5 mmol/L @ 12wk*
NCT02168491 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9 mg/dL as posted
-0.35 mmol/L @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-0.57 mmol/L @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-1.19 mmol/L @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
-0.81 mmol/L @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 52.2% (n=113) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 3 more results
46.5% (n=114) @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
43% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
40.6% (n=239) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence

+ 73 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · lixisenatide's landscape